Gerges Daniel, Grohmann Nathan, Trieu Vanessa, Brundage William, Sajisevi Mirabelle
Division of Otolaryngology University of Vermont Medical Center Burlington Vermont USA.
Robert Larner, M.D. College of Medicine at the University of Vermont Burlington Vermont USA.
Laryngoscope Investig Otolaryngol. 2020 Dec 24;6(1):150-154. doi: 10.1002/lio2.515. eCollection 2021 Feb.
To determine differences in incidence and duration of postoperative symptomatic hypocalcemia between those taking and those not taking proton pump inhibitors (PPIs) at the time of total or completion thyroidectomy.
A retrospective chart review of adult patients who underwent total or completion thyroidectomy at a tertiary medical center between January 2013 and January 2018 was performed. Development of symptomatic hypocalcemia, duration of symptoms, postoperative parathyroid hormone levels, PPI usage and emergency department (ED) visits were recorded.
Data from 371 patients were analyzed. Sixty of 371 (16.2%) patients developed symptomatic hypocalcemia. Sixteen of 89 (18.0%) patients on a PPI developed symptomatic hypocalcemia compared to 44 of 282 (15.6%) not on a PPI ( = .63). The overall average duration of symptoms was 4.3 days (SD [SD] 3.77 days). The average duration of symptoms in those on a PPI was 4.8 days (SD 2.8 days) compared to 4.2 days (SD 4.1 days) in those not on a PPI ( = 0.16). Six of 282 patients (2.1%) not taking a PPI had a postoperative ED visit, compared to two of the 89 patients (2.3%) taking a PPI ( = 1.00).
There was no clinically significant difference in incidence and duration of symptomatic hypocalcemia or ED visits after total or completion thyroidectomy between patients that were and were not taking PPIs perioperatively. While the decision to continue PPI should be made on an individual basis, these data suggest that patients may be counseled to continue their PPI perioperatively without increased risk of symptomatic hypocalcemia.
确定在全甲状腺切除术或甲状腺次全切除术后服用与未服用质子泵抑制剂(PPI)的患者中,术后症状性低钙血症的发生率及持续时间的差异。
对2013年1月至2018年1月在一家三级医疗中心接受全甲状腺切除术或甲状腺次全切除术的成年患者进行回顾性病历审查。记录症状性低钙血症的发生情况、症状持续时间、术后甲状旁腺激素水平、PPI使用情况及急诊就诊情况。
分析了371例患者的数据。371例患者中有60例(16.2%)出现症状性低钙血症。服用PPI的89例患者中有16例(18.0%)出现症状性低钙血症,未服用PPI的282例患者中有44例(15.6%)出现症状性低钙血症(P = 0.63)。症状的总体平均持续时间为4.3天(标准差[SD] 3.77天)。服用PPI患者的症状平均持续时间为4.8天(SD 2.8天),未服用PPI患者的症状平均持续时间为4.2天(SD 4.1天)(P = 0.16)。未服用PPI的282例患者中有6例(2.1%)术后到急诊科就诊,服用PPI的89例患者中有2例(2.3%)术后到急诊科就诊(P = 1.00)。
围手术期服用与未服用PPI的患者在全甲状腺切除术或甲状腺次全切除术后症状性低钙血症的发生率、持续时间或急诊就诊情况方面无临床显著差异。虽然是否继续使用PPI应根据个体情况决定,但这些数据表明,可建议患者在围手术期继续使用PPI,而不会增加症状性低钙血症的风险。
3级